Oral corticosteroid use and sarcopenia-related traits in older people with chronic airway disease: a population-based study
Open Access
- 27 July 2023
- journal article
- research article
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (5)
Abstract
Background: Sarcopenia is characterised by two major phenotypic components: low handgrip strength (HGS) and appendicular skeletal muscle index (ASMI). Oral corticosteroid (OCS) use is an important medication for acute respiratory exacerbations in patients with COPD and asthma. However, the association of OCS and sarcopenia components in older people is largely unexplored. The aim of this study was to examine the association between OCS use and HGS or ASMI in the general population and explore interactions with chronic airway diseases. Methods: From the population-based Rotterdam Study, 5054 participants (age 69.0±8.8 years; 56% females) were included in the cross-sectional analysis and 1324 in the longitudinal analysis. Associations between OCS and muscle strength and mass were analysed using linear regression models adjusted for age, sex, fat %, height, kidney function, smoking and comorbidities. Results: At baseline, ever-OCS users had lower handgrip strength (β= −0.48, 95% CI −0.84– −0.12) than never-OCS users, with cumulative frequency (≥10 OCS prescriptions)-dependent effects (β= −1.25, 95% CI −2.16– −0.33). COPD ever-OCS users, but not asthma, had lower handgrip strength (β= −0.98, 95% CI −1.91– −0.06) and lower lean mass (β= −0.14, 95% CI −0.27– −0.01) than never-OCS users. After 5.6 years of follow-up in those free of sarcopenia traits at baseline, COPD ever-OCS users developed lower handgrip strength (β= −1.64, 95% CI −2.87– −0.40) with frequency (β= −3.64, 95% CI −6.57– −0.72) and duration (β= −1.51, 95% CI −2.87– −0.15) association compared to never-OCS users. Conclusions: OCS use is associated with a decline in handgrip strength in people with COPD in a cumulative frequency and duration-dependent manner. Routine muscle examination may be necessary for patients with COPD.Keywords
Funding Information
- Fonds Wetenschappelijk Onderzoek (3G037618)
This publication has 37 references indexed in Scilit:
- Triggers and mechanisms of skeletal muscle wasting in chronic obstructive pulmonary diseaseThe International Journal of Biochemistry & Cell Biology, 2013
- Glucocorticoid-induced skeletal muscle atrophyThe International Journal of Biochemistry & Cell Biology, 2013
- Prevalence of oral glucocorticoid usage in the United States: A general population perspectiveArthritis Care & Research, 2012
- Polyanalgesic Consensus Conference 2012: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert PanelNeuromodulation: Technology at the Neural Interface, 2012
- Chronic obstructive pulmonary diseaseThe Lancet, 2012
- Sarcopenia: European consensus on definition and diagnosisAge and Ageing, 2010
- The cumulative burden of oral corticosteroid side effects and the economic implications of steroid useRespiratory Medicine, 2009
- Use of oral corticosteroids in the United KingdomQJM: An International Journal of Medicine, 2000
- Mechanisms of Muscle Wasting — The Role of the Ubiquitin–Proteasome PathwayNew England Journal of Medicine, 1996
- Corticosteroids Contribute to Muscle Weakness in Chronic Airflow ObstructionAmerican Journal of Respiratory and Critical Care Medicine, 1994